Syngene's Q1 Performance Chart 2023
Drug Updates

Syngene International Invests in Future Growth While Enjoying Robust Q1 Performance

Syngene International Limited is making significant waves in the healthcare sector. The company reported impressive first-quarter results with revenues up 26% to Rs. 832 crores and a PAT surge of 26% to Rs.93 crores. This strong financial footing allows Syngene to embark on strategic investments to pave the way for future growth.

These include the acquisition of a biologics manufacturing facility from Stelis Biopharma Ltd. With an additional 20,000 liters of biologics capacity, Syngene is well-positioned to dominate the contract development and manufacturing sector.

Further enhancing Syngene’s credibility and global outreach is the FDA’s approval of its Mangalore-based API manufacturing plant. This GMP-certified facility marks an important milestone for the company’s small molecule commercial manufacturing strategy.

Syngene’s plans also extend to bolstering its Research Services division. With the acquisition of additional land in Hyderabad, the company is making strategic moves to support its long-term growth ambitions in the research domain.


Leave a Reply

Your email address will not be published. Required fields are marked *